Advertisement

Melanoma pp 467-481 | Cite as

Surgery for Stage IV Metastatic Melanoma

  • David W. Ollila
  • Shachar Laks
  • Eddy C. Hsueh
Chapter

Abstract

The treatment of patients with stage IV metastatic melanoma has undergone a radical transformation since 2011. Previously, the only realistic curative-intent option for these patients was complete metastasectomy. This approach was only applicable to a highly select subgroup of patients with oligometastatic disease that was deemed resectable. This chapter briefly examines the newly approved targeted and immune-modulating therapies and discusses their role in the context of metastasectomy. Specifically, we discuss data supporting complete metastasectomy in patients with M1a, M1b, and M1c disease. Finally, we examine the role of combination therapy employing the newly approved, efficacious, agents, in a neoadjuvant fashion prior to complete metastasectomy, or as adjuvant therapy following metastasectomy.

Keywords

Melanoma Stage IV Metastasectomy Prognosis Metastasis Multidisciplinary care 

References

  1. 1.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.CrossRefGoogle Scholar
  4. 4.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.CrossRefGoogle Scholar
  6. 6.
    Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.CrossRefPubMedGoogle Scholar
  7. 7.
    Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.  https://doi.org/10.1200/JCO.2014.58.3377.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Barth A, Wanek L, Morton D. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193–201.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Wong S, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol. 2004;16(2):155–60.CrossRefPubMedGoogle Scholar
  10. 10.
    Martinez SR, Young SE. A rational surgical approach to the treatment of distant melanoma metastases. Cancer Treat Rev. 2008;34(7):614–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Feun L, Gutterman J, Burgess M, et al. The natural history of resectable metastatic melanoma (Stage IV A melanoma). Cancer. 1982;50:1656–63.CrossRefPubMedGoogle Scholar
  12. 12.
    Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol. 1999;71(4):209–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–11.  https://doi.org/10.1200/JCO.2013.49.8691.CrossRefPubMedGoogle Scholar
  14. 14.
    Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRefPubMedGoogle Scholar
  16. 16.
    Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–30.  https://doi.org/10.1200/JCO.2013.53.0105.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.CrossRefGoogle Scholar
  18. 18.
    Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366(3):207–15.  https://doi.org/10.1056/NEJMoa1105358.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    King AJ, Arnone MR, Bleam MR, Moss KG, Yang J, Fedorowicz KE, et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One. 2013;8(7):e67583.  https://doi.org/10.1371/journal.pone.0067583.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88.CrossRefGoogle Scholar
  21. 21.
    Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9.CrossRefGoogle Scholar
  22. 22.
    Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76.  https://doi.org/10.1056/NEJMoa1408868.CrossRefPubMedGoogle Scholar
  23. 23.
    Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015;372(26):2521–32.  https://doi.org/10.1056/NEJMoa1503093.CrossRefGoogle Scholar
  24. 24.
    Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.  https://doi.org/10.1200/JCO.2009.26.7609.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.  https://doi.org/10.1016/S1470-2045(15)70076-8.CrossRefPubMedGoogle Scholar
  26. 26.
    Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1.  https://doi.org/10.1056/NEJMc1509660.CrossRefPubMedGoogle Scholar
  27. 27.
    Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 2005;51(6):981–8.  https://doi.org/10.1373/clinchem.2004.045096.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Das Gupta T, Brasfield R. Metastatic melanoma of the gastrointestinal tract. Arch Surg. 1964;88:969–73.CrossRefGoogle Scholar
  29. 29.
    Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J. 2012;18(2):176–84.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med. 1990;322(9):605–12.  https://doi.org/10.1056/NEJM199003013220907.CrossRefPubMedGoogle Scholar
  31. 31.
    Digesu CS, Wiesel O, Vaporciyan AA, Colson YL. Management of sarcoma metastases to the lung. Surg Oncol Clin N Am. 2016;25(4):721–33.  https://doi.org/10.1016/j.soc.2016.05.005.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol. 2011;2011:763245.  https://doi.org/10.5402/2011/763245.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Arch Surg. 2004;139(9):961–6. discussion 6–7CrossRefPubMedGoogle Scholar
  34. 34.
    Ollila D, Essner R, Wanek L, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131(9):975.CrossRefPubMedGoogle Scholar
  35. 35.
    Amin MB, Edge S, Green F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.Google Scholar
  36. 36.
    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Forschner A, Eichner F, Amaral T, Keim U, Garbe C, Eigentler TK. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143(3):533–40.  https://doi.org/10.1007/s00432-016-2309-y.CrossRefPubMedGoogle Scholar
  38. 38.
    Overett TK, Shiu MH. Surgical treatment of distant metastatic melanoma. Indications and results. Cancer. 1985;56(5):1222–30.CrossRefPubMedGoogle Scholar
  39. 39.
    Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83(1):109–56.CrossRefPubMedGoogle Scholar
  40. 40.
    Meyer T, Merkel S, Goehl J, Hohenberger W. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89(9):1983–91.CrossRefPubMedGoogle Scholar
  41. 41.
    Markowitz J, Cosimi L, Carey R, et al. Prognosis after initial recurrence of cutaneous melanoma. Ann Surg. 1991;214:70–707.Google Scholar
  42. 42.
    Karakousis C, Velez A, Driscoll B, et al. Metastasectomy in malignant melanoma. Surgery. 1994;115:295–302.PubMedGoogle Scholar
  43. 43.
    Gadd M, Coit D. Recurrence patterns and outcome in 1019 patients undergoing axillary or inguinal lymphadenopathy for melanoma. Arch Surg. 1992;127:1412–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19(8):2547–55.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110(1):119–28. discussion 29CrossRefPubMedGoogle Scholar
  46. 46.
    Younes R, Abrao FC, Gross J. Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res. 2013;23(4):307–11.  https://doi.org/10.1097/CMR.0b013e3283632cbe.CrossRefPubMedGoogle Scholar
  47. 47.
    Casiraghi M, De Pas T, Maisonneuve P, Brambilla D, Ciprandi B, Galetta D, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the "international registry of lung metastases". J Thorac Oncol. 2011;6(8):1373–8.  https://doi.org/10.1097/JTO.0b013e3182208e58.CrossRefPubMedGoogle Scholar
  48. 48.
    Wong J, Euhus D, Morton D. Surgical resection for metastatic melanoma to the lung. Arch Surg. 1988;23:1091–5.CrossRefGoogle Scholar
  49. 49.
    Gorenstein LA, Putnam JB, Natarajan G, Balch CA, Roth JA. Improved survival after resection of pulmonary metastases from malignant melanoma [see comments]. Ann Thorac Surg. 1991;52(2):204–10.CrossRefPubMedGoogle Scholar
  50. 50.
    Harpole DH Jr, Johnson CM, Wolfe WG, George SL, Seigler HF. Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 1992;103(4):743–8. discussion 8–50PubMedGoogle Scholar
  51. 51.
    Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P. Long term results of lung metastectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.CrossRefPubMedGoogle Scholar
  52. 52.
    Dalrymple-Hay MJ, Rome PD, Kennedy C, Fulham M, McCaughan BC. Pulmonary metastatic melanoma—the survival benefit associated with positron emission tomography scanning. Eur J Cardiothorac Surg. 2002;21(4):611–4. discussion 4–5CrossRefPubMedGoogle Scholar
  53. 53.
    Petersen RP, Hanish SI, Haney JC, Miller CC 3rd, Burfeind WR Jr, Tyler DS, et al. Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg. 2007;133(1):104–10.CrossRefPubMedGoogle Scholar
  54. 54.
    Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG. Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol. 2007;14(10):2847–53.CrossRefPubMedGoogle Scholar
  55. 55.
    Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS, Morton DL. Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol. 2009;16(10):2834–9.  https://doi.org/10.1245/s10434-009-0583-5.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Finkelstein SE, Carrasquillo JA, Hoffman JM, Galen B, Choyke P, White DE, et al. A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy. Ann Surg Oncol. 2004;11(8):731–8.  https://doi.org/10.1245/ASO.2004.01.023.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Newman EA, Sabel MS, Nees AV, Schott A, Diehl KM, Cimmino VM, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946–52.CrossRefPubMedGoogle Scholar
  58. 58.
    Patel J, Didolkar M, Pickren J, Moore R. Metastatic pattern of malignant melanoma. A study of 216 autopsy studies. Am J Surg. 1978;135:807–10.CrossRefPubMedGoogle Scholar
  59. 59.
    Ricaniadis N, Konstadoulakis M, Walsh D, et al. Gastrointestinal metastases from malignant melanoma. Surg Oncol. 1995;4:105–10.CrossRefPubMedGoogle Scholar
  60. 60.
    Agrawal S, Yao T, Coit D. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol. 1999;6:336–44.CrossRefPubMedGoogle Scholar
  61. 61.
    Branum G, Epstein R, Leight G, et al. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery. 1991;109:127–31.PubMedGoogle Scholar
  62. 62.
    Klaase JM, Kroon BB. Surgery for melanoma metastatic to the gastrointestinal tract. Br J Surg. 1990;77(1):60–1.CrossRefPubMedGoogle Scholar
  63. 63.
    de la Monte S, Moore G, Hutchins G. Patterned distribution of metastasis from malignant melanoma in humans. Cancer Res. 1983;43:3427–33.PubMedGoogle Scholar
  64. 64.
    Wood T, DiFronzo L, Rose D, Haigh P, Stern S, Wanek L, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol. 2001;8:658–62.CrossRefPubMedGoogle Scholar
  65. 65.
    Gutman H, Hess K, Kokoysakis J, et al. Surgery for abdominal meatstases of cutaneous melanoma. World J Surg. 2001;25:750–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117(20):4740–06.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Ryu SW, Saw R, Scolyer RA, Crawford M, Thompson JF, Sandroussi C. Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries. J Surg Oncol. 2013;108(2):129–35.  https://doi.org/10.1002/jso.23361.CrossRefPubMedGoogle Scholar
  68. 68.
    Rose D, Essner R, Hughes T, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit Experience. Arch Surg. 2001;136(8):950–5.CrossRefPubMedGoogle Scholar
  69. 69.
    Collinson FJ, Lam TK, Bruijn WM, de Wilt JH, Lamont M, Thompson JF, et al. Long-term survival and occasional regression of distant melanoma metastases after adrenal metastasectomy. Ann Surg Oncol. 2008;15(6):1741–9.  https://doi.org/10.1245/s10434-008-9836-y.CrossRefPubMedGoogle Scholar
  70. 70.
    Flaherty DC, Deutsch GB, Kirchoff DD, Lee J, Huynh KT, Lee DY, et al. Adrenalectomy for metastatic melanoma: current role in the age of nonsurgical treatments. Am Surg. 2015;81(10):1005–9.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Romero Arenas MA, Sui D, Grubbs EG, Lee JE, Perrier ND. Adrenal metastectomy is safe in selected patients. World J Surg. 2014;38(6):1336–42.  https://doi.org/10.1007/s00268-014-2454-x.CrossRefPubMedGoogle Scholar
  72. 72.
    Sperti C, Moletta L, Patane G. Metastatic tumors to the pancreas: the role of surgery. World J Gastrointest Oncol. 2014;6(10):381–92.  https://doi.org/10.4251/wjgo.v6.i10.381.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Dong XD, DeMatos P, Prieto VG, Seigler HF. Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. Cancer. 1999;85(1):32–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Katz SC, Bowne WB, Wolchok JD, Busam KJ, Jaques DP, Coit DG. Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature. Am J Surg. 2007;193(4):493–7.  https://doi.org/10.1016/j.amjsurg.2006.06.033.CrossRefPubMedGoogle Scholar
  75. 75.
    de Wilt JH, McCarthy WH, Thompson JF. Surgical treatment of splenic metastases in patients with melanoma. J Am Coll Surg. 2003;197(1):38–43.  https://doi.org/10.1016/S1072-7515(03)00381-8.CrossRefPubMedGoogle Scholar
  76. 76.
    Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293–300.  https://doi.org/10.1200/JCO.2004.08.140.CrossRefPubMedGoogle Scholar
  77. 77.
    Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004;30(6):515–20.  https://doi.org/10.1016/j.ctrv.2004.05.001.CrossRefPubMedGoogle Scholar
  78. 78.
    Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a Randomized Clinical Trial. JAMA. 2016;316(4):401–9.  https://doi.org/10.1001/jama.2016.9839.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Morton DL, Mozzillo N, Thompson JF, Kashani-Sabet M, Kelley M, Gammon G. MMAIT-IV Clinical Trial Group. Multicenter double-blind phase 3 trial of Canvaxin vs. placebo as post surgical adjuvant in metastatic melanoma. Society of Surgical Oncology 59th Annual Cancer Symposium, San Diego, CA; 2006.Google Scholar
  80. 80.
    Morton DL, Mozzillo N, Thompson JF, Kelley MC, Faries M, Wagner J, et al. MMAIT Clinical Trials Group. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25(18s):8508.Google Scholar
  81. 81.
    Sondak VK, Liu PY, Warneke J. Surgical resection for Stage IV melanoma: a southwest oncology group trial. J Clin Oncol. 2006;24(Suppl):4575.Google Scholar
  82. 82.
    Koers K, Francken AB, Haanen JB, Woerdeman LA, van der Hage JA. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma. J Clin Oncol. 2013;31(16):e251–3.  https://doi.org/10.1200/JCO.2012.45.3845.CrossRefPubMedGoogle Scholar
  83. 83.
    Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol. 2013;31(3):e40–3.  https://doi.org/10.1200/JCO.2012.43.7061.CrossRefPubMedGoogle Scholar
  84. 84.
    Laks S, Brueske KA, Hsueh EC. Neoadjuvant treatment of melanoma: case reports and review. Exp Hematol Oncol. 2013;2(1):30.  https://doi.org/10.1186/2162-3619-2-30.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Melnik I, Lotem M, Yoffe B. A new role of vemurafenib as a neoadjuvant treatment of axillary and brain melanoma metastases. Case Rep Oncol Med. 2013;2013:794239.  https://doi.org/10.1155/2013/794239.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, et al. Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma. Ann Surg Oncol. 2017;24(1):135–41.  https://doi.org/10.1245/s10434-016-5537-0.CrossRefPubMedGoogle Scholar
  87. 87.
    Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16.  https://doi.org/10.1245/s10434-011-2108-2.CrossRefPubMedGoogle Scholar
  88. 88.
    Landry JC, Feng Y, Cohen SJ, Staley CA 3rd, Whittington R, Sigurdson ER, et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119(8):1521–7.  https://doi.org/10.1002/cncr.27890.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, et al. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013;20(9):3106–11.  https://doi.org/10.1245/s10434-013-2999-1.CrossRefPubMedGoogle Scholar
  90. 90.
    Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Retseck J, VanderWeele R, Lin HM, Lin Y, Butterfield LH, Tarhini AA. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. J Immunother Cancer. 2016;4:38.  https://doi.org/10.1186/s40425-016-0141-1.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    The International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • David W. Ollila
    • 1
  • Shachar Laks
    • 1
  • Eddy C. Hsueh
    • 2
  1. 1.Department of SurgeryUniversity of North Carolina at Chapel HillChapel HillUSA
  2. 2.Department of SurgerySaint Louis UniversitySt. LouisUSA

Personalised recommendations